Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Vaccines01:30

Cancer Vaccines

351
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
351

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning Model for Predicting Severe Adverse Events in Oncology Patients Using the US Food and Drug Administration Adverse Event Reporting System.

JCO clinical cancer informatics·2026
Same author

Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.

Cancer research·2025
Same author

Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets.

Neuro-oncology·2025
Same author

The Warburg Effect Revisited through Blood and Electron Flow.

Cancer research·2024
Same author

Hypermetabolic state is associated with circadian rhythm disruption in mouse and human cancer cells.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity.

Nature communications·2024
Same journal

Inhibiting PPM1D Perturbs Mitochondrial Integrity to Stimulate cGAS-STING Signaling and Antitumor Immunity.

Cancer research·2026
Same journal

BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.

Cancer research·2026
Same journal

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Cancer research·2026
Same journal

Opportunities to enhance cancer research through advocate-researcher partnerships.

Cancer research·2026
Same journal

EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.

Cancer research·2026
Same journal

Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clones.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

322

Clocking Cancer Immunotherapy Responses.

Catherine L Wang1,2, Xue Zhang2,3, Chi V Dang2,3,4,5

  • 1Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Cancer Research
|June 26, 2024
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy effectiveness is circadian, peaking in the evening. This immune timing, influenced by T-cell trafficking and PD-L1 expression, offers new strategies for optimizing cancer treatment.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 23, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

322
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Area of Science:

  • Immunology
  • Chronobiology
  • Cancer Research

Background:

  • Cancer immunotherapy has revolutionized treatment, but response variability remains a challenge.
  • Emerging evidence suggests biological rhythms influence immune system function.
  • Understanding these rhythms may unlock new therapeutic strategies.

Purpose of the Study:

  • To investigate the impact of circadian rhythms on cancer immunotherapy response.
  • To identify the underlying mechanisms driving the observed temporal effects.
  • To explore the clinical implications of chronotherapy in cancer treatment.

Main Methods:

  • Analysis of two recent studies examining immunotherapy responses in mouse cancer models.
  • Investigation of diurnal T-cell trafficking and PD-L1 expression on myeloid cells.
  • Correlation of findings with data from human cancer immunotherapy clinical trials.

Main Results:

  • Immunotherapy responses exhibit a significant circadian pattern, peaking in the evening (end of the resting phase).
  • This rhythmicity is linked to daily fluctuations in T-cell movement and programmed death-ligand 1 (PD-L1) expression.
  • Circadian immune behavior is consistent across different cancer models and observed in human patients.

Conclusions:

  • Tumor immunity operates on a circadian clock, impacting immunotherapy efficacy.
  • Time-of-day is a critical, previously unrecognized variable in cancer immunotherapy.
  • Further research into the immune circadian clock is essential for enhancing clinical immunotherapy outcomes.